Diphenylcyclopropenone Explained

Diphenylcyclopropenone (diphencyprone) is a topically administered experimental drug intended for treating alopecia areata and alopecia totalis.[1] Topical immunotherapy using diphenylcyclopropenone may also be an effective treatment option for recalcitrant warts.[2] It is not approved by either the Food and Drug Administration or the European Medicines Agency.[3]

Mechanism of action

Diphenylcyclopropenone triggers an immune response that is thought to oppose the action of the autoreactive cells that otherwise cause hair loss.[4] One hypothesis is that in response to DPCP treatment, the body will attempt to downregulate inflammation through a variety of pathways, resulting in a downregulation of the autoimmune response at the hair follicle. This autoinflammatory reaction would otherwise destroy body's hair follicles.

Studies

A study of 41 alopecia areata patients showed significant hair regrowth in 40% at 6 months, being sustained in two thirds of these after a 12-month-follow up-period.[5]

In a 2002 study for the treatment of warts, the responders consisted of 135 individuals (87.7%) that had complete clearance of warts. Reported adverse effects were local and included with pruritus (itching) (15.6%), with blistering (7.1%), and with eczematous reactions (eczema)(14.2%). The majority of the patients tolerated the treatment very well. One patient developed local impetigo (minor infection). Patients had an average of 5 treatments over a 6-month period.[2]

Chemical properties

The chemical properties of diphenylcyclopropenone are dominated by the strong polarization of the carbonyl group, which gives a partial positive charge with aromatic stabilization on the cyclopropene (cyclopropenium) ring and a partial negative charge on oxygen. The steric hindrance and partial charge on the cyclopropenium inhibit further electrophilic aromatic substitution there, but the phenyl rings are reactive. The cyclopropenium acts as a meta director.[6]

Electrophilic Lewis acids stabilize the charge separation, forming diphenylcyclopropenium ether or ester salts. Such compounds are extremely reactive electrophiles.[6]

Conversely, the oxygen is quite nucleophilic. Lux-Flood acids can abstract the oxygen: thus activated isocyanates effect imines; phosphorus sulfides or activated thioic acids effect the thione,[6] and a wide variety of electrophilic chlorinators, including oxalyl chloride, thionyl chloride, and phosphorus pentachloride, effect 3,3dichloro-1,2diphenyl­cyclopropene. The latter sees primary application as an electrophilical chlorinator itself, and catalyzes the action of the aforementioned chlorinators.[6] However, 3,3dichloro-1,2diphenyl­cyclopropene also ligates palladium for cross-coupling reactions,[7] and reacts with trichloroacetate to give diphenylcyclobutenedione upon aqueous workup.[6]

In other respects, the carbonyl is a typical electrophile, adding Grignard reagents, Knoevenagel enols, and enamines. The central ring is highly strained, and the presence of most transition metals or heating to 160 °C induces decarbonylation, although heating just below the decarbonylation temperature (150 °C) irreversibly forms a [3+2] dimer instead. Soft nucleophiles that typically add in conjugate typically open the ring instead, as do naïve attempts at reduction. However, careful hydroboration can reduce away the carbonyl.

See also

Notes and References

  1. Singh G, Lavanya M . Topical immunotherapy in alopecia areata . International Journal of Trichology . 2 . 1 . 36–9 . January 2010 . 21188022 . 3002409 . 10.4103/0974-7753.66911 . free .
  2. Upitis JA, Krol A . The use of diphenylcyclopropenone in the treatment of recalcitrant warts . . 6 . 3 . 214–7 . 2002 . 11951129 . 10.1007/s10227-001-0050-9 . 38571189 .
  3. Bulock KG, Cardia JP, Pavco PA, Levis WR . Diphencyprone Treatment of Alopecia Areata: Postulated Mechanism of Action and Prospects for Therapeutic Synergy with RNA Interference . The Journal of Investigative Dermatology. Symposium Proceedings . 17 . 2 . 16–8 . November 2015 . 26551938 . 10.1038/jidsymp.2015.33 . free .
  4. http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2009/10/WC500006138.pdf Public summary of positive opinion for orphan designation of diphenylcyclopropenone for the treatment of alopecia totalis
  5. Sotiriadis D, Patsatsi A, Lazaridou E, Kastanis A, Vakirlis E, Chrysomallis F . Topical immunotherapy with diphenylcyclopropenone in the treatment of chronic extensive alopecia areata . Clinical and Experimental Dermatology . 32 . 1 . 48–51 . January 2007 . 17004987 . 10.1111/j.1365-2230.2006.02256.x . 43725892 .
  6. Encyclopedia: 10.1002/047084289X.rn01532. Diphenylcyclopropenone. Tristan H.. Lambert. Eric D.. Nacsa. Encyclopedia of Reagents for Organic Synthesis. John Wiley & Sons.
  7. Book: Bennett, Clay S.. 3,3-Dichloro-1,2-diphenylcyclopropene. 2012. Encyclopedia of Reagents for Organic Synthesis. John Wiley & Sons. en. 10.1002/047084289x.rn01514. 978-0471936237 .